News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.


Jorge Garces is a proven senior executive with deep technology and development expertise

-Appointment underscores Epigenomics’ commitment to clinical, technical and operational excellence

-New President and Chief Scientific Officer to join Epigenomics on December 1, 2017

Berlin (Germany) and Germantown, MD (U.S.A.), November 5, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, announced today that the Supervisory Board appointed Dr. Jorge Garces as President and Chief Scientific Officer with effect from December 1, 2017.  Dr. Garces, who has held senior management positions in the U.S. molecular diagnostics industry, will become a member of the Executive Board of Epigenomics and oversee Operations, Research and Development, Clinical Affairs, Regulatory and Quality.

Dr. Garces, (46), has over 20 years of management experience in the molecular diagnostics and life sciences industries. Prior to joining Epigenomics, Jorge served as CEO and President of AltheaDx Inc. and previously at Enigma Diagnostics, Inc. in the same capacity.  Dr. Garces was also Vice President and Site Operations Manager at Hologic, Inc., where he led the development and submission to FDA for approval of their Cystic Fibrosis and HPV products. Additionally, he was a senior executive at GenMark Diagnostics and Third Wave Technologies. Earlier in his career, he held positions in major clinical diagnostic laboratories including Genzyme Genetics and Athena Diagnostics. Dr. Garces earned his doctorate in Cell and Molecular Biology from the City University of New York. He completed his post-doctoral training in neurobiology at the University of Massachusetts Medical School and received an MBA from the Kellogg Graduate School of Management at Northwestern University.

Heino von Prondzynski, Chairman of the Supervisory Board, stated: “The Supervisory Board is excited to add the significant executive management, clinical and technical expertise that Jorge brings to the Executive Board of Epigenomics.  Dr. Garces has continually demonstrated the ability to build strong teams that deliver innovative products to solve important clinical needs.  He is an example of the breadth and depth of experience and expertise that is necessary for Epigenomic’s continued growth.”

“I am excited to join the Epigenomics team and partner with all of the stakeholders as we build the foundation for significant growth.,” said Dr. Garces. “The Epigenomics blood-based cancer test, Epi proColon has the potential to significantly improve colon cancer screening rates and save lives.  Epigenomics’ liquid biopsy platform is uniquely positioned to play a major role in non-invasive cancer detection over the next couple of decades.”

Additionally, Dr. Uwe Staub, who has served as Chief Operating Officer and member of the Executive Board since 2013, will leave the company with effect March 31, 2018. The duration between the appointment of Dr. Garces and the departure of Dr. Staub will allow for an ample time for transition. “The Supervisory Board would like to express its great appreciation for Dr. Staub’s outstanding contributions to the development of the company”, added Heino von Prondzynski. “Dr. Staub played a critical leadership role during the development and product approval phase for the company. The Supervisory Board wishes Dr. Staub all the best for the future.”

About Epigenomics

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics’ lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epigenomics’ second product, Epi proLung®, is in development as a blood-based test for lung cancer detection.

For more information, visit

Epigenomics AG, Investor Relations, Peter Vogt, Geneststrasse 5, 10829 Berlin, Tel +49 (0) 30 24345 386, Fax +49 (0) 30 24345 555, E-Mail:

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.